Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Total therapy strategy with dasatinib-based induction and response-adapted consolidation for newly diagnosed adult Philadelphia chromosome-positive acute lymphoblastic leukemia
2010-019119-39Phase 2Completed
- Sponsor
- GIMEMA
- Start
- Jan 2012
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of dasatinib, clofarabine, cyclophosphamide and prednisone in acute lymphoblastic leukemia (ALL) (3 arms), sponsored by GIMEMA. Primary endpoints: Feasibility of total therapy strategy, PCR-negative cohort completion and 2 more. Started Jan 2012; status: completed.
02
Drugs
dasatinibclofarabinecyclophosphamideprednisone
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2010-019119-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019119-39.